KR101868326B1 - 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도 - Google Patents

파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도 Download PDF

Info

Publication number
KR101868326B1
KR101868326B1 KR1020127025501A KR20127025501A KR101868326B1 KR 101868326 B1 KR101868326 B1 KR 101868326B1 KR 1020127025501 A KR1020127025501 A KR 1020127025501A KR 20127025501 A KR20127025501 A KR 20127025501A KR 101868326 B1 KR101868326 B1 KR 101868326B1
Authority
KR
South Korea
Prior art keywords
carbidopa
levodopa
dosage form
delete delete
entacapone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127025501A
Other languages
English (en)
Korean (ko)
Other versions
KR20130006638A (ko
Inventor
유하 로우루
미코 쿠오파매키
유하 엘멘
페카 맨니스퇴
Original Assignee
오리온 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오리온 코포레이션 filed Critical 오리온 코포레이션
Publication of KR20130006638A publication Critical patent/KR20130006638A/ko
Application granted granted Critical
Publication of KR101868326B1 publication Critical patent/KR101868326B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127025501A 2010-03-04 2011-03-03 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도 Active KR101868326B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31039810P 2010-03-04 2010-03-04
US61/310,398 2010-03-04
US41282110P 2010-11-12 2010-11-12
US61/412,821 2010-11-12
US201161438416P 2011-02-01 2011-02-01
US61/438,416 2011-02-01
PCT/FI2011/000013 WO2011107653A2 (en) 2010-03-04 2011-03-03 Method for treating parkinson's disease

Publications (2)

Publication Number Publication Date
KR20130006638A KR20130006638A (ko) 2013-01-17
KR101868326B1 true KR101868326B1 (ko) 2018-06-19

Family

ID=44065577

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127025501A Active KR101868326B1 (ko) 2010-03-04 2011-03-03 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도

Country Status (14)

Country Link
US (4) US20130137729A1 (https=)
EP (1) EP2542220B1 (https=)
JP (2) JP5774610B2 (https=)
KR (1) KR101868326B1 (https=)
CN (1) CN102781424B (https=)
AU (1) AU2011222856B2 (https=)
BR (1) BR112012018256A8 (https=)
CA (1) CA2784819C (https=)
EA (1) EA026419B1 (https=)
ES (1) ES2614179T3 (https=)
IL (1) IL221744A (https=)
MX (1) MX336187B (https=)
WO (1) WO2011107653A2 (https=)
ZA (1) ZA201205836B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1907382T3 (pl) 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
BRPI0721213B1 (pt) 2007-01-31 2021-11-09 Bial - Portela & Ca, S.A. Uso de nitrocatecóis substituídos, e embalagem
WO2009116882A1 (en) 2008-03-17 2009-09-24 Portela & Ca., S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol
PT2413912T (pt) 2009-04-01 2019-06-11 Bial Portela & Ca Sa Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir
EA026419B1 (ru) * 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
JP6456143B2 (ja) 2011-12-13 2019-01-23 ノヴィファーマ，エス．アー． カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
CA3178035A1 (en) * 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
US9642810B2 (en) 2013-03-15 2017-05-09 Mylan Inc. Formulation containing carbidopa, levodopa, and entacapone
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
PT3341380T (pt) * 2015-08-27 2019-12-19 Prexton Therapeutics Sa Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa
EP3768263B1 (en) 2018-03-23 2025-10-29 LobSor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
BR112021009353A2 (pt) 2018-11-15 2021-11-23 Abbvie Inc Formulações farmacêuticas para administração subcutânea
CN112741808B (zh) * 2019-10-29 2024-02-06 南京济群医药科技股份有限公司 一种提高含盐酸苄丝肼口服固体组合物稳定性的方法
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
WO2021207634A1 (en) * 2020-04-10 2021-10-14 Senda Biosciences, Inc. Biomarkers related to parkinson's disease and methods of using the same
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017201A1 (en) * 1999-06-30 2003-01-23 Matti Virkki Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
KR20080012945A (ko) * 2005-06-08 2008-02-12 오리온 코포레이션 경구 용량 형태
WO2010020970A1 (en) * 2008-08-22 2010-02-25 Wockhardt Research Centre Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
WO2010020969A1 (en) 2008-08-22 2010-02-25 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
JP2015006373A (ja) * 2014-07-14 2015-01-15 株式会社大都技研 遊技台

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3462536A (en) 1960-07-22 1969-08-19 Merck & Co Inc Method of inhibiting decarboxylase
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
WO2005063696A2 (de) 2003-12-31 2005-07-14 Cilag Ag Neue kristalline formen von entacapone und deren herstellung
PT1751087E (pt) 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
PL1907382T3 (pl) * 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US8741342B2 (en) 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
MX2010009043A (es) 2008-02-28 2010-10-25 Bial Portela & Ca Sa Composicion farmaceutica para farmacos poco solubles.
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
EA026419B1 (ru) * 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
JP5551001B2 (ja) 2010-06-22 2014-07-16 株式会社Ｐｆｕ 摩擦係数推定装置および摩擦係数推定方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017201A1 (en) * 1999-06-30 2003-01-23 Matti Virkki Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
KR20080012945A (ko) * 2005-06-08 2008-02-12 오리온 코포레이션 경구 용량 형태
WO2010020970A1 (en) * 2008-08-22 2010-02-25 Wockhardt Research Centre Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
WO2010020969A1 (en) 2008-08-22 2010-02-25 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
JP2015006373A (ja) * 2014-07-14 2015-01-15 株式会社大都技研 遊技台

Also Published As

Publication number Publication date
AU2011222856B2 (en) 2015-10-15
HK1177896A1 (zh) 2013-08-30
EP2542220B1 (en) 2016-11-02
MX2012010161A (es) 2012-10-03
BR112012018256A8 (pt) 2017-12-19
US12521363B2 (en) 2026-01-13
JP5774610B2 (ja) 2015-09-09
WO2011107653A3 (en) 2011-11-03
CA2784819C (en) 2018-02-13
KR20130006638A (ko) 2013-01-17
AU2011222856A1 (en) 2012-07-26
EA026419B1 (ru) 2017-04-28
WO2011107653A2 (en) 2011-09-09
IL221744A (en) 2016-11-30
ZA201205836B (en) 2014-01-29
US20210085635A1 (en) 2021-03-25
EP2542220A2 (en) 2013-01-09
US20150150839A1 (en) 2015-06-04
ES2614179T3 (es) 2017-05-30
US11771675B2 (en) 2023-10-03
MX336187B (es) 2016-01-07
JP2013521263A (ja) 2013-06-10
US20130137729A1 (en) 2013-05-30
US20240050394A1 (en) 2024-02-15
EA201290865A1 (ru) 2013-02-28
BR112012018256A2 (https=) 2011-09-09
US10857120B2 (en) 2020-12-08
JP2015180644A (ja) 2015-10-15
WO2011107653A8 (en) 2012-08-02
CA2784819A1 (en) 2011-09-09
CN102781424B (zh) 2016-03-30
CN102781424A (zh) 2012-11-14

Similar Documents

Publication Publication Date Title
US12521363B2 (en) Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
JP6033373B2 (ja) レボドパの放出制御製剤及びその使用
KR101468738B1 (ko) 경구 용량 형태
KR20100126452A (ko) 난용성 약물용 약학적 조성물
WO2010023690A2 (en) Prolonged release formulation of amisulpride
US20150037405A1 (en) Pharmaceutical compositions of levodopa and carbidopa
AU2012101356A4 (en) Oral dosage form
HK1177896B (en) Use of levodopa, carbidopa and entacapone for treating parkinson's disease
ES2804348T3 (es) Formulaciones de liberación controlada de levodopa y usos de las mismas

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120927

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160226

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170822

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171218

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170822

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20171218

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20171019

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160226

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20180328

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20180319

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20171218

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20171019

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20160226

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180611

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180612

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20210603

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20210603

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20220602

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20220602

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240530

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20250529

Start annual number: 8

End annual number: 8